Guide
Girls who can be vaccinated for free are between 13 and 14 and a half years old; the approval of domestic vaccines for marketing is considered to be expected to reduce prices, increase supply, improve vaccine accessibility, and increase the possibility of being included in the immunization program in the future
2020 On May 18, a 10-year-old girl from Wuhan was waiting to be vaccinated with the domestically-made bivalent HPV vaccine. She was the first vaccinator in the country. Picture/People's Vision
丨 Reporter Ma Danmeng
Following Zhungeer Banner, Erdos, some girls in Another City can receive HPV vaccine for free. According to the Xiamen Municipal Health Commission, from 2020 to 2022, girls from 13 to 14 and a half years old in Xiamen can voluntarily receive HPV vaccination free of charge. The vaccination procedure is two doses within six months. This move may help prevent and control cervical cancer in China.
HPV is human papillomavirus, this type of virus is extremely common worldwide, among which high-risk HPV virus repeated infection can cause cervical cancer and other diseases in women. Cervical cancer is currently one of the most common gynecological tumors in China. It is highly infectious and highly lethal. According to a report issued by the International Agency for Research on Cancer, IARC, there were more than 100,000 new cases of cervical cancer in China in 2019 and 47,739 deaths. example.
The World Health Organization divides the prevention and control measures of women's cervical cancer into three levels. The primary prevention is HPV vaccination. In July 2017, the bivalent HPV vaccine produced by GlaxoSmithKline entered China and became the first domestic vaccine that is effective in preventing cervical cancer. It can prevent HPV high-risk types 16 and 18, these two subtypes. Cervical cancer caused by type recurrent infection accounts for about 85% of all cervical cancers.
Xiamen City decided to vaccinate the domestic bivalent HPV vaccine (trade name: Xinkening), produced by Xiamen Wantai Canghai Biotechnology Co., Ltd. This bivalent HPV vaccine is also the first domestically produced HPV vaccine. It was approved on the 30th and officially launched on the market in May 2020. The price is significantly lower than that of imported vaccines. It is the only domestic HPV vaccine that allows only two doses of specific age groups. The remaining HPV vaccines require three doses.
is approved for indications according to Xinkening, which is suitable for 9-45 years old women. Among them, 9-14 years old only need two doses in half a year, and 15-45 years old women still need three doses. A person from the Xiamen Municipal Health Commission told Caixin reporters that the maximum age for girls who can receive the vaccine for free in Xiamen has been set to 14 and a half years old. This is to ensure that the vaccinators have not yet reached the two-dose immunization program. 15 years old.
The minimum age to be able to enjoy free vaccination is set at 13, which is related to the government’s affordable expenditure, but the aforementioned person did not disclose the financial investment of Xiamen City in this project.
......
(This article comes from the original news site "Caixin". If you are interested in reading the full text, you can subscribe directly. Thank you!)
Inner Mongolia Zhungeer Banner first trial of free HPV vaccination When will the national promotion [2020- 08-09]
For the first time in the country, a region can receive HPV vaccine for free. According to the Health Bureau of Zhungeer Banner, Inner Mongolia, Zhungeer Banner held the launching ceremony of the free vaccination in early August. The free vaccination covers female students aged 13 to 18, benefiting nearly 10,000 people. However, national promotion is still difficult.
HPV is human papillomavirus, this type of virus is extremely common worldwide, among which high-risk HPV virus repeated infection can cause cervical cancer and other diseases in women. Cervical cancer is currently one of the most common gynecological tumors in China. It is highly infectious and highly lethal. According to a report issued by the International Agency for Research on Cancer, IARC, there were more than 100,000 new cases of cervical cancer in China in 2019 and 47,739 deaths. example. A survey published by the Chinese Journal of Cancer in 2017 showed that after 2001, the incidence and mortality of cervical cancer among Chinese urban and rural residents increased significantly, and the incidence tended to be younger.
The World Health Organization divides the prevention and control measures of women's cervical cancer into three levels. The primary prevention is HPV vaccination. In July 2017, the bivalent HPV vaccine produced by GlaxoSmithKline entered China and became the first domestic vaccine that is effective in preventing cervical cancer. It can prevent HPV high-risk types 16 and 18, these two subtypes. Cervical cancer caused by type recurrent infection accounts for about 85% of all cervical cancers.
firstThe domestic HPV vaccine was approved for marketing [2019-12-31]
As the end of 2019 is approaching, the development of domestic vaccines ushered in heavy news. According to the website of the State Food and Drug Administration, the bivalent human papillomavirus vaccine of Xiamen Wantai Canghai Biotechnology Co., Ltd. (hereinafter referred to as Wantai Bio) has been approved for marketing, and the product name is Cecolin. This is the first domestic human papillomavirus vaccine approved for use in women aged 9-45.
Human papillomavirus is also known as HPV virus. This type of virus is extremely common worldwide, among which high-risk HPV virus repeated infection can cause cervical cancer and other diseases in women. The domestic HPV vaccine approved by
is a bivalent vaccine, which mainly targets HPV types 16 and 18. More than 70% of cervical cancer and precancerous lesions are caused by repeated infections of these two viruses.
Nongfu Spring listed on the "myth of wealth creation" [2020-09-08]
selling water can make you rich, buying water company stocks can make money. On September 8, Nongfu Spring (09633.HK), a leading Chinese packaged drinking water company headquartered in Hangzhou, Zhejiang Province, was listed on the main board of the Hong Kong Stock Exchange, and its share price opened 85% higher, becoming the best-performing Hong Kong stock that day. The skyrocketing stock price of
has boosted shareholders' pockets. For every small shareholder who draws a lot of 200 shares, the book profit exceeds 2,100 yuan, which is about 1.4 times the minimum monthly salary of 1,500 yuan in Zhejiang Province; and the majority shareholder’s shareholding helps him make a net book profit of nearly 40 billion yuan a day , This profit alone can make him rank in the top 60 of China's rich list. The listed share price of Nongfu Spring of
opened at 39.80 Hong Kong dollars/share, which was as high as 39.85 Hong Kong dollars/share, which was 85.35% higher than the offer price of 21.5 Hong Kong dollars/share. As of today’s morning market close, Nongfu Spring temporarily reported 33.30 Hong Kong dollars per share, up 54.88%. Such crazy performance made Nongfu Spring an instant "rich-making myth". The biggest beneficiary is the company's founder and chairman Zhong Suihui . According to Forbes' 2019 China Rich List, Zhong Sui Sui's wealth is RMB 13.79 billion, ranking 186th. With the listing of Nongfu Spring, Zhong Sui Sui's wealth increased several times in just one day. Editor in charge of
|Bo Ren
Forum|Zhao Jinzhao Wang Bowen
@caixin.com
Inquiry: caixinhealth@caixin.com
-
-
-
-
-
-
-
-
-
-